Dr Bishal Gyawali casts his ascerbic eye over the key studies from ESMO 2022.
Starting with a commentary on the difficulties of oncologists from LMICs attending such meetings, he goes on to cover both the early cancer setting and de-escalation of treatment.
He covers the following studies:
|CANOPY-A: Phase III study of canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer|
|Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention|
|IMmotion010: Efficacy and safety from the phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at increased risk 5878 of recurrence after resection|
|Phase III randomized study comparing perioperative 5989 nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial|
|Adjuvant nivolumab plus ipilimumab vs placebo for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial|
|Primary results of the phase III KEYNOTE-412 study: Pembrolizumab with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)|
|Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study|
|Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)|
|Nivolumab plus ipilimumab 6-months treatment versus continuation in patients with advanced non-small cell lung cancer: Results of the randomized IFCT-1701 phase III trial|
|Comparison of abiraterone acetate and prednisolone or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer starting androgen deprivation therapy: Overall survival results of 2 randomised phase III trials from the STAMPEDE protocol in prostate ADT therapy|
|Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): a randomised phase 3 study|
|FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO|
|FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group|
|Pancreatic cancer trial - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study|
|Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma|
|Camrelizumab plus rivoceranib vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma: A randomized, phase III trial|
|Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma|
|DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumours|
|Treatment with tumour-infiltrating lymphocytes versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial|
Dr Gyawali’s thoughts on the latest breast and ovarian data will be coming soon in a second video.